- ￥6756
- abinscience
- 234.4 ng/mL - 15,000 ng/mL
- \
- France
- DB941038
- 2026年03月03日
14 年钻石会员
企业认证
相关产品推荐更多 >
Mirzotamab ELISA Kit, Mirzotamab ELISA试剂盒
￥6756Pacmilimab ELISA Kit, Pacmilimab ELISA试剂盒
￥6756Anti-MPXV A29L Human IgG ELISA Kit, Anti-MPXV A29L Human IgG ELISA试剂盒
￥3588SARS-CoV-2 Nucleocapsid Protein (NP) ELISA Kit, SARS-CoV-2 Nucleocapsid Protein (NP) ELISA试剂盒
￥3268Monkeypox Virus (MPXV) B6R Antigen ELISA Kit, Monkeypox Virus (MPXV) B6R Antigen ELISA试剂盒
￥3588
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 库存：
999
- 供应商：
abinscience
- 检测范围：
234.4 ng/mL - 15,000 ng/mL
- 检测方法：
Colorimetric
- 应用：
ELISA
- 适应物种：
Not Species Specific
- 标记物：
Unconjugated
- 样本：
Plasma, Serum
- 灵敏度：
\
- 规格：
96T
| Product name | Ranibizumab ELISA Kit |
|---|---|
| Catalog No. | DB941038 |
| Applications | ELISA |
| Accession | P15692 |
| Stability and Storage | When the kit was stored at the recommended temperature for 6 months, the signal intensity decreased by less than 20%. For unopened kits, if you want to prolong the storage time, please store the Standard, Detection A, Detection B and Microplate at - 20℃, the rest reagents should be store at 4℃. |
| Detection method | Colorimetric |
| Sample type | Plasma, Serum |
| Assay type | Quantitative |
| Sensitivity | \ |
| Background | Ranibizumab, sold under the brand name Lucentis among others, is a monoclonal antibody fragment (Fab) created from the same parent mouse antibody as bevacizumab. It is an anti-angiogenic that is approved to treat the "wet" type of age-related macular degeneration (AMD, also ARMD), diabetic retinopathy, and macular edema due to branch retinal vein occlusion or central retinal vein occlusion. Ranibizumab was developed by Genentech and marketed by them in the United States, and elsewhere by Novartis, under the brand name Lucentis. Ranibizumab (Lucentis) was approved for medical use in the United States in June 2006, and in the European Union in January 2007. Medical uses In the United States, ranibizumab is indicated for the treatment of neovascular (wet) age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, diabetic retinopathy, and myopic choroidal neovascularization. In the European Union, ranibizumab is indicated for the treatment of neovascular (wet) age-related macular degeneration, visual impairment due to diabetic macular edema, proliferative diabetic retinopathy, visual impairment due to macular edema secondary to retinal vein occlusion, and visual impairment due to choroidal neovascularisation. It is used for age-related wet macular degeneration. Its effectiveness is similar to that of bevacizumab and aflibercept. A 2023 systematic review update found that while ranibizumab and bevacizumab provide similar functional outcomes in diabetic macular edema, there is low-certainty evidence suggesting that ranibizumab is more effective in reducing central retinal thickness than bevacizumab. Susvimo is a reformulation of ranibizumab suitable for injection via ocular implant. Susvimo was approved for medical use in the United States in October 2021. Side effects A 2014 Cochrane review did not find a difference between bevacizumab and ranibizumab in deaths or total severe side effects when used for macular degeneration. There, however, was not a lot of evidence, and thus this conclusion is not that certain. Ranibizumab does appear to result in a lower risk of stomach and intestinal problems. It is also associated with a low rate of eye related side effects. Serious adverse events related to the injection procedure occurred with an incidence rate of less than 1% and included endophthalmitis, retinal detachment, and traumatic cataracts. Other serious ocular adverse events observed among ranibizumab-treated patients (incidence rate < 1%) included intraocular inflammation and blindness. Interactions No significant interactions are known. Pharmacology Ranibizumab is a monoclonal antibody that inhibits angiogenesis by inhibiting vascular endothelial growth factor A, a mechanism similar to that of bevacizumab. Society and culture Legal status Biosimilars Byooviz was approved for medical use in the European Union in August 2021. Ranibizumab-nuna (Byooviz) was approved for medical use in the United States in September 2021. In India, Lupin Limited received marketing approval for its biosimilar of Ranibizumab. In June 2022, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Ranivisio, intended for the treatment of neovascular (wet) age-related macular degeneration, visual impairment due to macular edema or choroidal neovascularization, and proliferative diabetic retinopathy. The applicant for this medicinal product is Midas Pharma GmbH. Ranivisio was approved for medical use in the European Union in August 2022. Ranibizumab-eqrn (Cimerli) was approved for medical use in the United States in August 2022. In September 2022, the CHMP adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Ximluci, intended for the treatment of neovascular (wet) age-related macular degeneration, visual impairment due to diabetic macular edema, proliferative diabetic retinopathy, visual impairment due to macular edema secondary to retinal vein occlusion (branch RVO or central RVO), and visual impairment due to choroidal neovascularization. The applicant for this medicinal product is STADA Arzneimittel AG. Ximluci was approved for medical use in the European Union in November 2022. In November 2023, the CHMP adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Rimmyrah, intended for the treatment of neovascular (wet) age-related macular degeneration, visual impairment due to diabetic macular edema, proliferative diabetic retinopathy, visual impairment due to macular edema secondary to retinal vein occlusion (branch RVO or central RVO), and visual impairment due to choroidal neovascularization. The applicant for this medicinal product is QILU PHARMA SPAIN S.L. Rimmyrah is a biosimilar medicinal product that is highly similar to the reference product Lucentis (ranibizumab), which was authorized in the EU in January 2007. Rimmyrah was approved for medical use in the European Union in January 2024. In January 2024, Sandoz signed an agreement to acquire ranibizumab-eqrn, the biosimilar version of ranibizumab branded as Cimerli from Coherus BioSciences, Inc. for an upfront cash purchase payment of US$170 million. In July 2024, the CHMP adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Ranibizumab Midas, intended for the treatment of neovascular (wet) age-related macular degeneration, visual impairment due to diabetic macular edema, proliferative diabetic retinopathy, visual impairment due to macular edema secondary to retinal vein occlusion and visual impairment due to choroidal neovascularization. The applicant for this medicinal product is Midas Pharma GmbH. Ranibizumab Midas is a biosimilar medicinal product and is a duplicate of Ranivisio. Economics Its effectiveness is similar to that of bevacizumab. Its rates of side effects also appear similar. However, ranibizumab typically costs $2,000 a dose, while the equivalent dose of bevacizumab typically costs $50. Genentech offered secret rebates to about 300 ophthalmologists in an apparent inducement to get them to use more ranibizumab rather than the less expensive bevacizumab. In 2008, bevacizumab cost Medicare only $20 million for about 480,000 injections, while ranibizumab cost Medicare $537 million for only 337,000 injections. A small study showed no superior effect of ranibizumab versus bevacizumab in direct comparison. The initial results of the larger Comparison of Age-related Macular Degeneration Treatments Trials (CATT) found that the two drugs "had equivalent effects on visual acuity when administered according to the same schedule;" however, serious adverse events were more common in the bevacizumab arm of the trial. According to a 2012 meta-analysis, the results of several subsequent head-to-head trials found that the two therapies performed equally at restoring visual acuity. A 2012 meta-analysis focused specifically on safety issues concluded that the rates of several adverse events were higher with bevacizumab, although the absolute rates of ocular serious adverse events were low with both therapies: ocular adverse events were about 2.8 times as frequent with bevacizumab than with ranibizumab. |
| Target | Ranibizumab |
| Range | 234.4 ng/mL - 15,000 ng/mL |
| Recovery | 80-120% |
| Alternative Names | Fab-12 variant Y0317, RhuFab, CAS: 347396-82-1 |
| Clone ID | \ |
| Shipping | 2-8 ℃ |
| Note | For Research Use Only. |
Abinscience, founded in 2023 and located in the innovation technology center in Strasbourg, France, is the core research reagent brand of ProteoGenix. Focusing on the development and production of life science research reagents, Abinscience takes "Empowering Bioscience Discovery" as its vision, and is committed to providing high-quality and innovative biological reagent products and technical solutions for global researchers.
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验该产品被引用文献
Kolosova A Y, Shim W B, Yang Z Y, et al. Direct competitive ELISA based on a monoclonal antibody for detection of aflatoxin B 1. Stabilization of ELISA kit components and application to grain samples[J]. Analytical and bioanalytical chemistry, 2006, 384: 286-632.
相关实验
licanming 请问有无人用过assaydesigns公司的PKC Kinase Activity Assay Kit（cat NO:EKS-420A）?可否说一下应用的经验？注意事项等？还有，该试剂盒的说明书有几处地方不是很懂，请大家帮忙看一下： 1、To avoid cross contamination, change disposable pipette tips between the addition of each standard
RAT/MOUSE GROWTH HORMONE ELISA KIT
实验原理 This assay is a Sandwich ELISA based, sequentially, on: 1) capture of rat or mouse Growth Hormone molecules from samples to the wells of a microtiter plate coated by a pre-titered amount of anti-Growth Hormone
R&D Systems Quantikine® 人高分子量脂联素ELISA试剂盒
素敏感性，常常与TNF-α 的作用相反。1,4 它作用在肝脏和骨骼肌上，促进葡萄糖吸收，刺激脂肪酸吸收和氧化，并抑制肝糖原异生和脂肪生成。5 通常还认为脂联素通过在一定程度上抑制TNF-α 产生并拮抗TNF-α 对血管内皮细胞的影响而抑制组织炎症。5,6 在成年人中，循环的脂联素水平与脂肪组织量成反比，而血浆中HMW脂联素水平的降低与代谢综合征相关的状态有关，包括上身肥胖、血脂异常和胰岛素抵抗。1,7 R&D Systems 提供了首个ELISA 试剂盒，能够准确定量人类血清和血
技术资料暂无技术资料 索取技术资料
文献支持
Ranibizumab ELISA Kit, Ranibizumab ELISA试剂盒
￥6756
